Atlas Trials

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Clinical trial NCT06008119 · RECRUITING

Trial details

NCT number
NCT06008119
Sponsor
Shanghai Kechow Pharma, Inc.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Colorectal Cancer Metastatic
Start date
2023-10-25
Primary completion
2026-12-24
Enrollment
165

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.